EANS-News: Epigenomics AG Enrolls First Participant in its FIT comparative study with Epi proColon®

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/New Products/molecular diagnostics

Berlin, Germany, and Seattle, WA, U.S.A., April 11, 2012 (euro adhoc)
- Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American
cancer molecular diagnostics company, today announced the start of
the head-to-head comparative study of Epi proColon® with fecal
immunochemical testing (FIT) for colorectal cancer detection.
Meanwhile the first study subject has been enrolled.

As previously announced, the US Food and Drug Administration (FDA)
has requested Epigenomics to perform a head-to-head comparative study
for colorectal cancer detection through comparison with FIT for the
purpose of demonstrating non-inferiority of Epi proColon® to FIT.

Site recruitment and initiation is currently ongoing with the aim of
including up to 75 clinical sites. The study will compare FIT and Epi
proColon® analyses for 100 subjects with confirmed cancer (post
colonoscopy) and 200 asymptomatic average risk individuals
(pre-colonoscopy). Epigenomics plans to complete this study in the
second half of 2012 and the results will be an integral part of the
company's Modular Premarket Approval (PMA) submission to the FDA. The
Company already submitted the first two PMA modules and is on track
to file its third and fourth modules in the second quarter and second
half of 2012, respectively.

-Ends-

Contact Epigenomics AG
Antje Zeise Manager IR | PR
Epigenomics AG
Tel +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer
earlier and more accurately, leading to improved outcomes for
patients. Epigenomics' lead product, Epi proColon®, is a blood-based
test for the early detection of colorectal cancer, which is currently
marketed in Europe and is in development for the U.S.A. The Company's
technology and products have been validated through multiple
partnerships with leading global diagnostic companies including
Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an
international company with operations in Europe and the U.S.A.

Epigenomics' legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States of America. The analytical and
clinical performance characteristics of any product based on this
technology which may be sold at some future time in the U.S.A. have
not been established.

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English